ATE345811T1 - Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen - Google Patents

Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen

Info

Publication number
ATE345811T1
ATE345811T1 AT00908254T AT00908254T ATE345811T1 AT E345811 T1 ATE345811 T1 AT E345811T1 AT 00908254 T AT00908254 T AT 00908254T AT 00908254 T AT00908254 T AT 00908254T AT E345811 T1 ATE345811 T1 AT E345811T1
Authority
AT
Austria
Prior art keywords
neurotrophin
methods
disorders
hypomobility
treat gastrointestinal
Prior art date
Application number
AT00908254T
Other languages
English (en)
Inventor
Jesse M Cedarbaum
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE345811T1 publication Critical patent/ATE345811T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00908254T 1999-01-15 2000-01-11 Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen ATE345811T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/232,171 US6656474B1 (en) 1999-01-15 1999-01-15 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Publications (1)

Publication Number Publication Date
ATE345811T1 true ATE345811T1 (de) 2006-12-15

Family

ID=22872143

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00908254T ATE345811T1 (de) 1999-01-15 2000-01-11 Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen

Country Status (13)

Country Link
US (1) US6656474B1 (de)
EP (1) EP1146899B1 (de)
JP (1) JP4489303B2 (de)
AT (1) ATE345811T1 (de)
AU (1) AU775860B2 (de)
CA (1) CA2360252C (de)
DE (1) DE60031951D1 (de)
IL (2) IL144315A0 (de)
NO (1) NO329488B1 (de)
NZ (1) NZ512968A (de)
TR (2) TR200201875T2 (de)
WO (1) WO2000041719A1 (de)
ZA (1) ZA200105799B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU7142201A (en) * 2000-06-22 2002-01-02 Genentech Inc Agonist anti-trk-c monoclonal antibodies
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1620127A4 (de) * 2003-03-20 2007-04-04 Rinat Neuroscience Corp Verfahren zur behandlung von taxol-induzierten darmstörungen
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US5962404A (en) * 1989-08-28 1999-10-05 Yeda Research & Development Co., Ltd. Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
WO1994006455A1 (en) * 1992-09-14 1994-03-31 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
DE69535221T2 (de) 1994-04-25 2007-09-13 Genentech, Inc., South San Francisco Cardiotrophin und verwendung davon
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6211142B1 (en) 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP3540912B2 (ja) * 1997-03-28 2004-07-07 京セラ株式会社 釣糸用ガイド部材
WO1998049308A1 (en) 1997-04-25 1998-11-05 Genentech, Inc. Ngf variants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor

Also Published As

Publication number Publication date
ZA200105799B (en) 2002-01-24
US6656474B1 (en) 2003-12-02
CA2360252A1 (en) 2000-07-20
JP4489303B2 (ja) 2010-06-23
TR200201875T2 (tr) 2002-09-23
EP1146899B1 (de) 2006-11-22
NO329488B1 (no) 2010-10-25
JP2002534479A (ja) 2002-10-15
NO20013493D0 (no) 2001-07-13
EP1146899A4 (de) 2003-03-05
IL144315A (en) 2008-08-07
NO20013493L (no) 2001-09-17
EP1146899A1 (de) 2001-10-24
CA2360252C (en) 2010-11-02
AU2963600A (en) 2000-08-01
TR200102767T2 (tr) 2002-04-22
AU775860B2 (en) 2004-08-19
IL144315A0 (en) 2002-05-23
WO2000041719A9 (en) 2001-08-30
NZ512968A (en) 2003-09-26
WO2000041719A1 (en) 2000-07-20
DE60031951D1 (de) 2007-01-04

Similar Documents

Publication Publication Date Title
ATE345811T1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE60120667D1 (de) Methoden und mittel zur behandlung von bandscheibenverschleiss
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69813898D1 (de) Substituierte porphyrinen
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE215822T1 (de) Verwendung von rapamycin zur behandlung von anämie
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE374619T1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE209909T1 (de) Verwendung von tachykinin-antagonisten zur behandlung von erbrechen
DE50111057D1 (de) Hochverzweigte polymere zur antiknitterausrüstung von cellulosehaltigen textilien
DE69721756D1 (de) Paroxetine zur behandlung von depression
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE409732T1 (de) Methoden zur vorbehandlung von schuhen
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
SE0003126D0 (sv) Method of treatment
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
DE50210718D1 (de) Verfahren zur behandlung von schlamm
DE60213230D1 (de) Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
ATE371445T1 (de) Verfahren zur prävention und/oder behandlung von asthma mit parabromophenacyl bromide (pbpb)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties